Mabvax Therapeutics (MBVX) 10-Q 12 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Oct. 31, 2013
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'TELK	'
Entity Registrant Name	'TELIK INC	'
Entity Central Index Key	'0001109196	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	4,583,096

CONDENSED_BALANCE_SHEETS

CONDENSED BALANCE SHEETS (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$2,084	$4,747
Short-term investments	1,113	'
Interest and other receivables	7	5
Prepaids and other current assets	457	626
Total current assets	3,661	5,378
Restricted investments	'	250
Other assets	35	'
Total assets	3,696	5,628
Current liabilities:	'	'
Accounts payable	22	151
Accrued clinical trial costs	24	154
Accrued compensation	248	313
Accrued liabilities	370	481
Accrued contingent lease termination fee	591	'
Short-term deferred rent	'	4
Current portion of facility exit costs	'	1,022
Total current liabilities	1,255	2,125
Noncurrent portion of facility exit costs	'	441
Commitments and contingencies	'	'
Stockholders' equity:	'	'
Common stock	46	27
Additional paid-in capital	555,139	551,335
Accumulated deficit	-552,744	-548,300
Total stockholders' equity	2,441	3,062
Total liabilities and stockholders' equity	$3,696	$5,628

CONDENSED_STATEMENTS_OF_COMPRE

CONDENSED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Operating costs and expenses:	'	'	'	'
Research and development	$380	$867	$1,694	$2,788
General and administrative	742	1,011	2,761	3,423
Total operating costs and expenses	1,122	1,878	4,455	6,211
Loss from operations	-1,122	-1,878	-4,455	-6,211
Interest and other income, net	1	2	11	6
Net loss	-1,121	-1,876	-4,444	-6,205
Other comprehensive income, net of tax:	'	'	'	'
Changes in net unrealized gains on investments	'	'	'	'
Comprehensive loss	($1,121)	($1,876)	($4,444)	($6,205)
Basic and diluted net loss per share	($0.25)	($0.78)	($1)	($3.07)
Shares used to calculate basic and diluted net loss per share	4,572	2,395	4,445	2,021

CONDENSED_STATEMENTS_OF_CASH_F

CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:	'	'
Net loss	($4,444)	($6,205)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation	'	1
Stock-based compensation expense	226	550
Changes in assets and liabilities:	'	'
Other receivables	-2	3
Prepaid expenses and other current assets	169	-95
Other assets	-35	'
Accounts payable	-129	-63
Accrued liabilities	-310	-125
Accrued facility exit costs and contingent lease termination fee	-872	-1,107
Net cash used in operating activities	-5,397	-7,041
Cash flows from investing activities:	'	'
Purchases of investments	-2,513	-4,507
Sales of investments	250	'
Maturities of investments	1,400	6,161
Net cash (used in) provided by investing activities	-863	1,654
Cash flows from financing activities:	'	'
Proceeds from issuance of common stock	3,597	1,983
Net cash provided by financing activities	3,597	1,983
Net decrease in cash and cash equivalents	-2,663	-3,404
Cash and cash equivalents at beginning of period	4,747	9,046
Cash and cash equivalents at end of period	$2,084	$5,642

Nature_of_Operations_and_Going

Nature of Operations and Going Concern	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Nature of Operations and Going Concern	'
	1.     Nature of Operations and Going Concern
	Business Overview
	Telik, Inc. (“Telik,” “we” or the “Company”) was incorporated in the state of Delaware in October 1988. We are engaged in the discovery and development of small molecule therapeutics. We operate in only one business segment.
	We have incurred net losses since inception and we expect to incur substantial losses for at least the next several years as we continue our research and development activities. To date, we have funded operations primarily through the sale of equity securities, non-equity payments from collaborators and interest income. The process of developing our products will require significant additional research and development, preclinical testing and clinical trials, as well as regulatory approval. We expect these activities, together with general and administrative expenses, to result in substantial operating losses for the foreseeable future. We will not receive product revenue unless we, or our collaborative partners, complete clinical trials, obtain regulatory approval and successfully commercialize one or more of our products.
	Going Concern
	We believe our existing cash resources will only be sufficient to fund our projected operating requirements into the first quarter of 2014. Our ability to continue as a going concern is subject to significant uncertainty, including but not limited to, our ability to raise adequate capital to fund our current clinical development plan. We have incurred significant losses from operations and expect to continue to incur losses for the foreseeable future. While we were able to raise $3.6 million through the sale of our common stock in the nine months ended September 30, 2013, we cannot provide any assurances that we will be successful in obtaining additional funding, if at all. We have been and are currently seeking collaborative arrangements with corporate partners to fund the development and commercialization of TELINTRA, our lead product candidate. We are also seeking, and evaluating options to raise, additional funds through equity or debt financings or other sources such as research grants from non-profit organizations, to enable us to commence a Phase 3 registration trial of TELINTRA. To this end, we have retained a financial advisory firm to assist in these efforts and to explore and recommend strategic alternatives. These alternatives could include partnerships involving one or more of our product candidates, financings, the sale of company assets, in whole or in part, ceasing operations, or some other arrangement through which the value of our assets to stockholders could be optimized. We may have to further restructure our operations to conserve resources. These conditions raise a substantial doubt about our ability to continue as a going concern.
	The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles applicable to a going concern which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Our ability to continue as a going concern is dependent upon our ability to obtain additional equity or debt financing, attain further operating efficiencies and, ultimately, to generate revenue. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
	Stock Offerings
	In August 2011, we filed a shelf registration statement on Form S-3 to offer and sell, from time to time, equity securities in one or more offerings up to a total dollar amount of $25.0 million. On August 30, 2011, we entered into an At Market Issuance Sales Agreement, or Sales Agreement, with McNicoll, Lewis & Vlak LLC, or MLV, pursuant to which we may issue and sell shares of our common stock having an aggregate offering price of up to $7.0 million from time to time through MLV as our sales agent. For the nine months ended September 30, 2013, we sold 1,893,896 shares of our common stock and received approximately $3.6 million in net proceeds under the Sales Agreement after deducting commissions and other related expenses. Since entering into the Sales Agreement, we have sold 2,782,887 shares of our common stock and received approximately $5.8 million in net proceeds.
	Our ability to sell shares of our common stock pursuant to the Sales Agreement is subject to share volume limitations, market conditions and our continued listing on the Nasdaq Capital Market. There is no assurance that we may be able to raise any additional funds in the future under the Sales Agreement.

Basis_of_Presentation_and_Summ

Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Basis of Presentation and Summary of Significant Accounting Policies	'
	2.     Basis of Presentation and Summary of Significant Accounting Policies
	We have prepared the accompanying condensed financial statements in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Act of 1934, or the Exchange Act. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. We believe all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included herein. Operating results for the three and nine months ended September 30, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013 or any other future period. The condensed balance sheet at December 31, 2012 has been derived from the audited financial statements at that date. You should read these condensed financial statements and notes in conjunction with our audited financial statements for the year ended December 31, 2012, which are included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 15, 2013.
	Use of Estimates
	In preparing our financial statements to conform with GAAP, we make estimates and assumptions that affect the amounts reported in our financial statements and accompanying notes. Actual results may differ from these estimates.

Employee_StockBased_Compensati

Employee Stock-Based Compensation	9 Months Ended
	Sep. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Employee Stock-Based Compensation	'
	3.     Employee Stock-Based Compensation
	Stock-based Compensation
	Total estimated stock-based compensation expense, related to all of our share-based payment awards recognized under ASC 718, “Compensation—Stock Compensation” was comprised of the following:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013		2012
		(In thousands)
	Research and development	$	—		$	61		$	92	$	224
	General and administrative		3			85			134		326
	Stock-based compensation expense before taxes		3			146			226		550
	Effect on net loss	$	3		$	146		$	226	$	550
	Because we had a net operating loss carryforward as of September 30, 2013, no tax benefits for the tax deductions related to stock-based compensation expense were recognized in our Condensed Statements of Comprehensive Loss. Additionally, no incremental tax benefits were recognized from stock options exercised in the nine months ended September 30, 2013 and 2012, which would have resulted in a reclassification to reduce net cash provided by operating activities with an offsetting increase in net cash provided by financing activities. As of September 30, 2013, $7,800 of total unrecognized compensation costs, net of forfeitures, related to non-vested service based awards is expected to be recognized over a weighted average period of 2.01 years.
	Valuation Assumptions
	We used the Black-Scholes-Merton option valuation model, or the Black-Scholes model, to determine the stock-based expense recognized under ASC 718. Our expected stock-price volatility assumption was based solely on the weighted average of the historical volatility as there was insufficient traded option activity for us to use implied volatility. The expected term of stock awards under our Employee Stock Purchase Plan, or ESPP, was based on the weighted average purchase periods of each offering. The expected term of stock options granted was based on the simplified method in accordance with Staff Accounting Bulletin No. 110, or SAB 110, as our historical share option exercise experience did not provide a reasonable basis for estimation. The risk-free interest rate was based on the U.S. Treasury yield for a period consistent with the expected term of the stock award in effect at the time of the grant. Assumptions used in the Black-Scholes model were as follows:
		Stock Option Plans						Stock Purchase Plan
		Nine Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013		2012
	Weighted expected stock price volatility		114	%		111	%		—		107.8	%
	Weighted risk-free interest rate		1.08	%		1.29	%		—		0.21	%
	Weighted expected life (in years)		6.08			6.08			—		1.25
	Weighted expected dividend yield		—			—			—		—
	There were no stock options granted and no new ESPP participants enrolled during the three months ended September 30, 2013 and 2012. For the nine months ended September 30, 2013, we did not have any new participants enrolled in the ESPP.

Basic_and_Diluted_Net_Loss_per

Basic and Diluted Net Loss per Share	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Basic and Diluted Net Loss per Share	'
	4.     Basic and Diluted Net Loss per Share
	Basic and diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period.
	Weighted average outstanding options to purchase 278,913 and 330,985 shares of our common stock before application of the treasury stock method for the three months ended September 30, 2013 and 2012; and 285,389 and 340,665 shares of our common stock before application of the treasury stock method for the nine months ended September 30, 2013 and 2012 were excluded from the diluted net loss per common share calculations because inclusion of such options would be anti-dilutive.

Fair_Value_Measurements_on_a_R

Fair Value Measurements on a Recurring Basis	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements on a Recurring Basis	'
	5.     Fair Value Measurements on a Recurring Basis
	We measure certain financial assets at fair value on a recurring basis, including cash equivalents and available-for-sale securities. The fair value of these financial assets was determined based on a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. Government agency securities held in our account are recorded at their estimated fair value. These securities generally have market prices from multiple sources and it can be difficult to select the best individual price directly from the quoted prices in the active markets. Therefore we use Level 2 inputs for the valuation of these securities. Using the Level 2 inputs, a “consensus price” or a weighted average price for each of these securities can be derived from a distribution-curve-based algorithm which includes market prices obtained from a variety of industrial standard data providers (e.g. Bloomberg), security master files from large financial institutions and other third-party sources.
	The following table presents information about our financial assets that are measured at fair value on a recurring basis as of September 30, 2013 and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value:
				Fair Value Measurement at September 30, 2013 Using
		September 30,		Quoted Prices in		Significant Other		Significant
		2013		Active Markets		Observable		Unobservable
				for Identical		Inputs (Level 2)		Inputs (Level 3)
				Assets (Level 1)
		(in thousands)
	Available-for-sale securities:
	Money market funds	$	1,738	$	1,738	$	—	$	—
	US government agencies		1,113		—		1,113		—
	Total	$	2,851	$	1,738	$	1,113	$	—
	The following table presents information about our financial assets that are measured at fair value on a recurring basis as of December 31, 2012, and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value.
				Fair Value Measurement at December 31, 2012 Using
		December 31,		Quoted Prices in		Significant Other		Significant
		2012		Active Markets		Observable		Unobservable
				for Identical		Inputs (Level 2)		Inputs (Level 3)
				Assets (Level 1)
		(in thousands)
	Available-for-sale securities:
	Money market funds	$	85	$	85	$	—	$	—
	US government agencies		3,575		—		3,575		—
	Total	$	3,660	$	85	$	3,575	$	—
	There were no transfers between Level 1 and Level 2 measurements in the three and nine months ended September 30, 2013 and in the year ended December 31, 2012.

Cash_Cash_Equivalents_Investme

Cash, Cash Equivalents, Investments and Restricted Investments	9 Months Ended
	Sep. 30, 2013
Cash And Cash Equivalents [Abstract]	'
Cash, Cash Equivalents, Investments and Restricted Investments	'
	6.     Cash, Cash Equivalents, Investments and Restricted Investments
	The following is a summary of estimated fair value of cash and cash equivalents, investments and restricted investments:
		September 30,		December 31,
		2013		2012
		(in thousands)
	Certificate of deposits	$	—	$	250
	US government agencies		1,113		3,575
	Cash and money market funds		2,084		1,172
	Total	$	3,197	$	4,997
	Reported as:
	Cash and cash equivalents	$	2,084	$	4,747
	Short-term investments		1,113		—
	Restricted investments		—		250
	Total	$	3,197	$	4,997
	There were no realized gains or losses on sales of available-for-sale securities for the three and nine months ended September 30, 2013 and the year ended December 31, 2012. There were no unrealized gains or losses on available-for-sale securities as of September 30, 2013 or December 31, 2012.
	As of September 30, 2013 and December 31, 2012, all marketable debt securities held as available-for-sale are expected to mature in less than a year.

Facility_Exit_Costs_and_Accrue

Facility Exit Costs and Accrued Contingent Lease Termination Fee	9 Months Ended
	Sep. 30, 2013
Restructuring And Related Activities [Abstract]	'
Facility Exit Costs and Accrued Contingent Lease Termination Fee	'
	7.     Facility Exit Costs and Accrued Contingent Lease Termination Fee
	In November 2010, we ceased the use of our facility at 3165 Porter Drive in Palo Alto, California and subleased the facility to a tenant for the remaining contractual term of our master lease, which is through May 2014. As a result, we recorded a charge of $4.7 million which included the estimated fair value of future lease-related payments less estimated net income from sublease rental offset by a reduction of $335,000 in the balance of deferred rent related to the facility as of November 30, 2010.
	On February 19, 2013, we entered into an agreement with our landlord, ARE San Francisco No.24, LLC, or ARE, pursuant to which the premises was voluntarily surrendered, the master lease and sublease were terminated as of February 28, 2013, we were relieved of further obligations under the master lease and further rights to rental income under the sublease, and we agreed to pay a termination fee to ARE of approximately $0.7 million. Prior to the termination of these agreements, the remaining lease payments to ARE through the end of the master lease totaled approximately $4.5 million and the remaining sublease income to Telik through the same period totaled approximately $3.2 million. In addition to the termination fee, if we receive $15 million or more in additional financing in the aggregate, an additional termination fee of $591,000 will be due to ARE, but otherwise be forgiven. As a result of the termination agreement, we reversed the remaining facility exit cost liability, recorded $591,000 as accrued contingent lease termination fee and included the net charge in general and administrative expenses in the Condensed Statements of Comprehensive Loss in the quarter ended March 31, 2013.
	The following table summarizes the activities related to accrued facility exit costs for the nine months ended September 30, 2013 (in thousands):
	Balance as of December 31, 2012	$	1,463
	Lease payments made during the period		(603	)
	Sublease income received during the period		418
	Termination fee paid or applied using deposit		(714	)
	Amount transferred to contingent termination fee		(564	)
	Balance as of September 30, 2013	$	—

Commitments_Contingencies

Commitments & Contingencies	9 Months Ended
	Sep. 30, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Commitments & Contingencies	'
	8.     Commitments & Contingencies
	Operating Leases
	On February 27, 2013, we entered into a 21-month lease agreement for 3,075 square feet of office space at 2100 Geng Road in Palo Alto, California and relocated our corporate offices to this facility in March 2013. Upon execution of the agreement, we paid the sublessor the first month’s rent and we paid the second month’s rent on March 28, 2013, and deposited into an escrow account approximately $219,000 which represents the total rent due for the remaining term (May 1, 2013 thru November 30, 2014).
	We have no future rental payments under our non-cancelable operating leases as of September 30, 2013 and none for the year 2014 and beyond. We recorded a $591,000 contingent lease termination fee, in connection with the termination of our master lease and sublease of our Porter Drive facility, which is payable to ARE if we receive $15 million or more in additional financing in the aggregate.

Basis_of_Presentation_and_Summ1

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Use of Estimates	'
	Use of Estimates
	In preparing our financial statements to conform with GAAP, we make estimates and assumptions that affect the amounts reported in our financial statements and accompanying notes. Actual results may differ from these estimates.

Employee_StockBased_Compensati1

Employee Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Schedule of Estimated Stock-Based Compensation Expense	'
	Total estimated stock-based compensation expense, related to all of our share-based payment awards recognized under ASC 718, “Compensation—Stock Compensation” was comprised of the following:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013		2012
		(In thousands)
	Research and development	$	—		$	61		$	92	$	224
	General and administrative		3			85			134		326
	Stock-based compensation expense before taxes		3			146			226		550
	Effect on net loss	$	3		$	146		$	226	$	550
Assumptions Used in the Black-Scholes Model	'
	Assumptions used in the Black-Scholes model were as follows:
		Stock Option Plans						Stock Purchase Plan
		Nine Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013		2012
	Weighted expected stock price volatility		114	%		111	%		—		107.8	%
	Weighted risk-free interest rate		1.08	%		1.29	%		—		0.21	%
	Weighted expected life (in years)		6.08			6.08			—		1.25
	Weighted expected dividend yield		—			—			—		—

Fair_Value_Measurements_on_a_R1

Fair Value Measurements on a Recurring Basis (Tables)	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Schedule of Financial Assets Measured at Fair Value on a Recurring Basis	'
	The following table presents information about our financial assets that are measured at fair value on a recurring basis as of September 30, 2013 and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value:
				Fair Value Measurement at September 30, 2013 Using
		September 30,		Quoted Prices in		Significant Other		Significant
		2013		Active Markets		Observable		Unobservable
				for Identical		Inputs (Level 2)		Inputs (Level 3)
				Assets (Level 1)
		(in thousands)
	Available-for-sale securities:
	Money market funds	$	1,738	$	1,738	$	—	$	—
	US government agencies		1,113		—		1,113		—
	Total	$	2,851	$	1,738	$	1,113	$	—
	The following table presents information about our financial assets that are measured at fair value on a recurring basis as of December 31, 2012, and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value.
				Fair Value Measurement at December 31, 2012 Using
		December 31,		Quoted Prices in		Significant Other		Significant
		2012		Active Markets		Observable		Unobservable
				for Identical		Inputs (Level 2)		Inputs (Level 3)
				Assets (Level 1)
		(in thousands)
	Available-for-sale securities:
	Money market funds	$	85	$	85	$	—	$	—
	US government agencies		3,575		—		3,575		—
	Total	$	3,660	$	85	$	3,575	$	—

Cash_Cash_Equivalents_Investme1

Cash, Cash Equivalents, Investments and Restricted Investments (Tables)	9 Months Ended
	Sep. 30, 2013
Cash And Cash Equivalents [Abstract]	'
Summary of Estimated Fair Value of Cash and Cash Equivalents, Investments and Restricted Investments	'
	The following is a summary of estimated fair value of cash and cash equivalents, investments and restricted investments:
		September 30,		December 31,
		2013		2012
		(in thousands)
	Certificate of deposits	$	—	$	250
	US government agencies		1,113		3,575
	Cash and money market funds		2,084		1,172
	Total	$	3,197	$	4,997
	Reported as:
	Cash and cash equivalents	$	2,084	$	4,747
	Short-term investments		1,113		—
	Restricted investments		—		250
	Total	$	3,197	$	4,997

Facility_Exit_Costs_and_Accrue1

Facility Exit Costs and Accrued Contingent Lease Termination Fee (Tables)	9 Months Ended
	Sep. 30, 2013
Restructuring And Related Activities [Abstract]	'
Schedule of Activities Related to Accrued Facility Exit Costs	'
	The following table summarizes the activities related to accrued facility exit costs for the nine months ended September 30, 2013 (in thousands):
	Balance as of December 31, 2012	$	1,463
	Lease payments made during the period		(603	)
	Sublease income received during the period		418
	Termination fee paid or applied using deposit		(714	)
	Amount transferred to contingent termination fee		(564	)
	Balance as of September 30, 2013	$	—

Nature_of_Operations_and_Going1

Nature of Operations and Going Concern - Additional Information (Detail) (USD $)	1 Months Ended		9 Months Ended	25 Months Ended
In Millions, except Share data, unless otherwise specified	Aug. 31, 2011	Aug. 30, 2011	Sep. 30, 2013	Sep. 30, 2013
			Segment
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'	'	'	'
Number of business segment	'	'	1	'
Number of equity securities offerings	'One or more	'	'	'
Net proceeds after deducting commissions and other related expenses	'	'	$3.60	$5.80
Equity securities offering amount	25	'	'	'
Shares of common stock sold during the period	'	'	1,893,896	2,782,887
Common stock having an aggregate offering price	'	$7	'	'
Date of entering into Market Issuance Sales Agreement	'	'	30-Aug-11	'

Employee_StockBased_Compensati2

Employee Stock-Based Compensation - Schedule of Estimated Stock-Based Compensation Expense (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation expense before taxes	$3	$146	$226	$550
Effect on net loss	3	146	226	550
Research and Development [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation expense	'	61	92	224
General and Administrative [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation expense	$3	$85	$134	$326

Employee_StockBased_Compensati3

Employee Stock-Based Compensation - Additional Information (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'
Recognized tax benefits	$0	'
Incremental tax benefits from stock options exercised	0	0
Unrecognized compensation costs, net of forfeitures, related non-vested service awards	$7,800	'
Expected to be recognized over weighted average period (in years)	'2 years 4 days	'

Employee_StockBased_Compensati4

Employee Stock-Based Compensation - Assumptions Used in the Black-Scholes Model (Detail)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Stock Option Plans [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Weighted expected stock price volatility	114.00%	111.00%
Weighted risk-free interest rate	1.08%	1.29%
Weighted expected life (in years)	'6 years 29 days	'6 years 29 days
Weighted expected dividend yield	'	'
Stock Purchase Plan [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Weighted expected stock price volatility	'	107.80%
Weighted risk-free interest rate	'	0.21%
Weighted expected life (in years)	'0 years	'1 year 3 months
Weighted expected dividend yield	'	'

Employee_StockBased_Compensati5

Employee Stock-Based Compensation - New ESPP Offerings and Stock Option Granted - Additional Information (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'	'
New ESPP offerings	0	0	0
Stock option granted	0	0	'

Basic_and_Diluted_Net_Loss_per1

Basic and Diluted Net Loss per Share - Additional Information (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Earnings Per Share [Abstract]	'	'	'	'
Shares of common stock excluded from diluted net loss per common share calculations	278,913	330,985	285,389	340,665

Fair_Value_Measurements_on_a_R2

Fair Value Measurements on a Recurring Basis - Schedule of Financial Assets Measured at Fair Value on a Recurring Basis (Detail) (Fair Value, Measurements, Recurring [Member], USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	$2,851	$3,660
US Government Agencies [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	1,113	3,575
Money Market Funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	1,738	85
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	1,738	85
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | US Government Agencies [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	'	'
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Money Market Funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	1,738	85
Significant Other Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	1,113	3,575
Significant Other Observable Inputs (Level 2) [Member] | US Government Agencies [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	1,113	3,575
Significant Other Observable Inputs (Level 2) [Member] | Money Market Funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	'	'
Significant Unobservable Inputs (Level 3) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	'	'
Significant Unobservable Inputs (Level 3) [Member] | US Government Agencies [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	'	'
Significant Unobservable Inputs (Level 3) [Member] | Money Market Funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	'	'

Fair_Value_Measurements_on_a_R3

Fair Value Measurements on a Recurring Basis - Additional Information (Detail) (USD $)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2013	Dec. 31, 2012
Fair Value Disclosures [Abstract]	'	'	'
Transfer of securities between Level 1 and Level 2 measurements	$0	$0	$0

Cash_Cash_Equivalents_Investme2

Cash, Cash Equivalents, Investments and Restricted Investments - Summary of Estimated Fair Value of Cash and Cash Equivalents, Investments and Restricted Investments (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Total estimated fair value	$3,197	$4,997	'	'
Cash and cash equivalents	2,084	4,747	5,642	9,046
Short-term investments	1,113	'	'	'
Restricted investments	'	250	'	'
Reported as [Member]	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Cash and cash equivalents	2,084	4,747	'	'
Short-term investments	1,113	'	'	'
Restricted investments	'	250	'	'
Total	3,197	4,997	'	'
Certificate of Deposits [Member]	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Total estimated fair value	'	250	'	'
US Government Agencies [Member]	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Total estimated fair value	1,113	3,575	'	'
Cash and Money Market Funds [Member]	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Total estimated fair value	$2,084	$1,172	'	'

Cash_Cash_Equivalents_Investme3

Cash, Cash Equivalents, Investments and Restricted Investments - Additional Information (Detail) (USD $)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2013	Dec. 31, 2012
Cash Cash Equivalents Investments And Restricted Investments [Abstract]	'	'	'
Realized gains or losses on sales of available-for-sale investments	$0	$0	$0
Unrealized gains or losses on available-for-sale securities	$0	$0	$0
Available-for-sale security maximum maturity period	'	'1 year	'1 year

Facility_Exit_Costs_and_Accrue2

Facility Exit Costs and Accrued Contingent Lease Termination Fee - Additional Information (Detail) (USD $)	1 Months Ended	9 Months Ended	1 Months Ended
	Feb. 28, 2013	Sep. 30, 2013	Nov. 30, 2010
			Facility Exit Costs [Member]
Restructuring Cost and Reserve [Line Items]	'	'	'
Estimated fair value of future lease related payments	'	'	$4,700,000
Deferred rent	'	'	335,000
Lease and sublease expiration date	'	'	31-May-14
Termination of master as well as sublease	'	28-Feb-13	'
Termination fees payable	'	700,000	'
Remaining master lease payments	4,500,000	'	'
Additional termination fee due	'	591,000	'
Contingent lease termination fee	'	591,000	'
Additional financing amount	'	15,000,000	'
Remaining sublease income	$3,200,000	'	'

Facility_Exit_Costs_and_Accrue3

Facility Exit Costs and Accrued Contingent Lease Termination Fee - Schedule of Activities Related to Accrued Facility Exit Costs (Detail) (Facility Exit Costs [Member], USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013
Facility Exit Costs [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Balance as of December 31, 2012	$1,463
Lease payments made during the period	-603
Sublease income received during the period	418
Termination fee paid or applied using deposit	-714
Amount transferred to contingent termination fee	-564
Balance as of September 30, 2013	'

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	1 Months Ended	9 Months Ended
	Feb. 27, 2013	Sep. 30, 2013
	sqft
Operating Leased Assets [Line Items]	'	'
Contingent lease termination fee	'	$591,000
Additional financing or licensing payments	'	15,000,000
2100 Geng Road in Palo Alto, California [Member]	'	'
Operating Leased Assets [Line Items]	'	'
Term of lease agreement	'21 months	'
Amount deposited in escrow for rent due for remaining lease period	'	219,000
Remaining term of rent deposited in escrow	'	'May 1, 2013 thru November 30, 2014
Number of square feet	3,075	'
Future rental payments under our non-cancelable operating leases	'	0
Future rental payments under our non-cancelable operating leases for the year 2014 and thereafter	'	0
Porter Drive [Member]	'	'
Operating Leased Assets [Line Items]	'	'
Contingent lease termination fee	'	591,000
Additional financing or licensing payments	'	$15,000,000